JNJ · News · 20261101N

Impella Clinical Outcomes

JOHNSON & JOHNSON · 2026-11-01 · Importance 64 · Surprise 56

Three analyses presented at TCT 2026 examined Impella-supported high-risk percutaneous coronary intervention (HRPCI) patients across U.S. and European hospitals. In the PROTECT III analysis of 578 patients, in-hospital all-cause mortality was 4.7%, compared with an estimated approximately 8% in the CHIP-BCIS3 study. The reported analyses also found lower in-hospital cardiovascular mortality and lower 30- and 90-day mortality rates than those recently reported in CHIP-BCIS3.

Key facts

• Johnson & Johnson announced three clinical analyses at the TCT 2026 symposium reporting positive survival and patient outcomes for patients using Impella heart pumps during and after high-risk percutaneous coronary intervention (HRPCI). source
• In the PROTECT III study, 578 Impella-supported HRPCI patients had 4.7% in-hospital all-cause mortality, compared with estimated mortality of approximately 8% in CHIP-BCIS3. source
• Johnson & Johnson reported three clinical analyses at TCT 2026 based on real-world and observational registry data from 1,379 HRPCI patients across hospitals in the U.S. and Europe; the analyses showed lower in-hospital cardiovascular mortality and lower 30- and 90-day mortality rates than those recently reported in CHIP-BCIS3. source
• Johnson & Johnson reported results from three clinical analyses of Impella heart pump support, comparing outcomes with rates reported in the CHIP-BCIS3 clinical trial. source
• The three Impella clinical analyses examined 1,379 patients across U.S. and European hospitals. source